Snyder, S. H. Drugs and the Brain (W. H. Freeman & Co., 1986).
Shulgin, A. T. The background and chemistry of MDMA. J. Psychoactive Drugs 18, 291–304 (1986).
Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181–1197 (2016).
Noller, G. E., Frampton, C. M. & Yazar-Klosinski, B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am. J. Drug Alcohol Abuse 44, 37–46 (2018).
Johnson, M. W. & Griffiths, R. R. Potential therapeutic effects of psilocybin. Neurotherapeutics 14, 734–740 (2017).
Mitchell, J. M. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat. Med. 27, 1025–1033 (2021).
Mithoefer, M. C. et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J. Psychopharmacol. 27, 28–39 (2013).
Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402–1411 (2021).
Zarate, C. A. et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 63, 856–864 (2006).
Nichols, D. E. Psychedelics. Pharmacol. Rev. 68, 264–355 (2016).
Nardou, R. et al. Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature 569, 116–120 (2019).
Russo, S. J. et al. The addicted synapse: mechanisms of synaptic and structural plasticity in nucleus accumbens. Trends Neurosci. 33, 267–276 (2010).
Bedi, G., Hyman, D. & De Wit, H. Is ecstasy an ‘empathogen’? Effects of 3,4- methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others. Biol. Psychiatry 68, 1134–1140 (2010).
Holze, F. et al. Distinct acute effects of LSD, MDMA, and d-amphetamine in healthy subjects. Neuropsychopharmacology 45, 462–471 (2020).
Niesters, M., Martini, C. & Dahan, A. Ketamine for chronic pain: risks and benefits. Br. J. Clin. Pharmacol. 77, 357–367 (2014).
MačiIulaitis, R., Kontrimavičiute, V., Bressolle, F. M. M. & Briedis, V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. Hum. Exp. Toxicol. 27, 181–194 (2008).
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J. & Brandt, S. D. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 167, 107933 (2020).
Autry, A. E. et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475, 91–95 (2011).
Tzschentke, T. M. Measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict. Biol. 12, 227–462 (2007).
Kolbrich, E. A. et al. Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J. Clin. Psychopharmacol. 28, 432–440 (2008).
Madsen, M. K. et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44, 1328–1334 (2019).
Schmid, Y. et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol. Psychiatry 78, 544–553 (2015).
Abraham, W. C. & Bear, M. F. Metaplasticity: the plasticity of synaptic plasticity. Trends Neurosci. 19, 126–130 (1996).
Cho, K. K. A., Khibnik, L., Philpot, B. D. & Bear, M. F. The ratio of NR2A/B NMDA receptor subunits determines the qualities of ocular dominance plasticity in visual cortex. Proc. Natl Acad. Sci. USA 106, 5377–5382 (2009).
Dölen, G., Darvishzadeh, A., Huang, K. W. & Malenka, R. C. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 501, 179–184 (2013).
Hung, L. W. L. L. W. et al. Gating of social reward by oxytocin in the ventral tegmental area. Science 357, 1406–1411 (2017).
Bennett, J. P. & Snyder, S. H. Stereospecific binding of d-lysergic acid diethylamide (LSD) to brain membranes: relationship to serotonin receptors. Brain Res. 94, 523–544 (1975).
Preller, K. H. et al. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr. Biol. 27, 451–457 (2017).
Kometer, M., Schmidt, A., Jäncke, L. & Vollenweider, F. X. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J. Neurosci. 33, 10544–10551 (2013).
Rudnick, G. & Wall, S. C. The molecular mechanism of ‘ecstasy’ [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl Acad. Sci. USA 89, 1817–1821 (1992).
Murphy, T. J. & Murnane, K. S. The serotonin 2C receptor agonist WAY-163909 attenuates ketamine-induced hypothermia in mice. Eur. J. Pharmacol. 842, 255–261 (2019).
McClure-Begley, T. D. & Roth, B. L. The promises and perils of psychedelic pharmacology for psychiatry. Nat. Rev. Drug Discov. 21, 463–473 (2022).
Kim, K. et al. Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor. Cell 182, 1574–1588.e19 (2020).
Maillet, E. L. et al. Noribogaine is a G-protein biased κ-opioid receptor agonist. Neuropharmacology 99, 675–688 (2015).
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T. & Monteggia, L. M. Effects of a ketamine metabolite on synaptic NMDAR function. Nature 546, E1–E3 (2017).
Esterlis, I. et al. Ketamine-induced reduction in mGluR5 availability is associated with an antidepressant response: an [11C]ABP688 and PET imaging study in depression. Mol. Psychiatry 23, 824–832 (2018).
Lau, L. W., Cua, R., Keough, M. B., Haylock-Jacobs, S. & Yong, V. W. Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat. Rev. Neurosci. 14, 722–729 (2013).
Oh, S. Y., Lee, S.-J., Jung, Y. H., Lee, H. J. & Han, H. J. Arachidonic acid promotes skin wound healing through induction of human MSC migration by MT3-MMP-mediated fibronectin degradation. Cell Death Dis. 6, e1750 (2015).
Cussac, L.-A. et al. TRPV4 channel mediates adventitial fibroblast activation and adventitial remodeling in pulmonary hypertension. Am. J. Physiol. 318, L135–L146 (2020).
Shan, Z.-G. et al. Upregulation of tubulointerstitial nephritis antigen like 1 promotes gastric cancer growth and metastasis by regulating multiple matrix metallopeptidase expression. J. Gastroenterol. Hepatol. 36, 196–203 (2021).
Chakraborty, S. & Ain, R. Nitric-oxide synthase trafficking inducer is a pleiotropic regulator of endothelial cell function and signaling. J. Biol. Chem. 292, 6600–6620 (2017).
Uckelmann, H. et al. Extracellular matrix protein Matrilin-4 regulates stress-induced HSC proliferation via CXCR4. J. Exp. Med. 213, 1961–1971 (2016).
Tjong, W.-Y. & Lin, H.-H. The role of the RGD motif in CD97/ADGRE5-and EMR2/ADGRE2-modulated tumor angiogenesis. Biochem. Biophys. Res. Commun. 520, 243–249 (2019).
Cai, H. et al. Roundabout 4 regulates blood-tumor barrier permeability through the modulation of ZO-1, occludin, and claudin-5 expression. J. Neuropathol. Exp. Neurol. 74, 25–37 (2015).
Carulli, D., de Winter, F. & Verhaagen, J. Semaphorins in adult nervous system plasticity and disease. Front. Synaptic Neurosci. 13, 672891 (2021).
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B. & Thompson, S. M. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc. Natl Acad. Sci. USA 118, e2022489118 (2021).
Moda-Sava, R. N. et al. Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 364, eaat8078 (2019).
Vargas, M. V. et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science 379, 700–706 (2023).
Young, M. B. et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology 234, 2883–2895 (2017).
Flanagan, T. W. & Nichols, C. D. Psychedelics as anti-inflammatory agents. Int. Rev. Psychiatry 30, 363–375 (2018).
Schindler, E. A. D. Psychedelics in the treatment of headache and chronic pain disorders. Curr. Top. Behav. Neurosci. 56, 261–285 (2022).
Ly, C. et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 23, 3170–3182 (2018).
Shao, L.-X. et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 109, 2535–2544.e4 (2021).
Ali, F. et al. Ketamine disinhibits dendrites and enhances calcium signals in prefrontal dendritic spines. Nat. Commun. 11, 72 (2020).
Castrén, E. & Monteggia, L. M. Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biol. Psychiatry 90, 128–136 (2021).
Crawford, D. C., Ramirez, D. M. O., Trauterman, B., Monteggia, L. M. & Kavalali, E. T. Selective molecular impairment of spontaneous neurotransmission modulates synaptic efficacy. Nat. Commun. 8, 14436 (2017).
Kim, J.-W. et al. Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation. Nat. Neurosci. 24, 1100–1109 (2021).
Kuypers, K. P. C. et al. Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology 233, 3395–3403 (2016).
Davis, A. K., Barrett, F. S. & Griffiths, R. R. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J. Context. Behav. Sci. 15, 39–45 (2020).
Agin-Liebes, G. et al. Prospective examination of the therapeutic role of psychological flexibility and cognitive reappraisal in the ceremonial use of ayahuasca. J. Psychopharmacol. 36, 295–308 (2022).
Lorenz, K. Der Kumpan in der Umwelt des Vogels. J. Ornithol. 83, 137–213 (1935).
Woolley, S. M. N. & Rubel, E. W. Vocal memory and learning in adult Bengalese finches with regenerated hair cells. J. Neurosci. 22, 7774–7787 (2002).
Hartshorne, J. K., Tenenbaum, J. B. & Pinker, S. A critical period for second language acquisition: evidence from 2/3 million English speakers. Cognition 177, 263–277 (2018).
Hensch, T. K. & Quinlan, E. M. Critical periods in amblyopia. Vis. Neurosci. 35, E014 (2018).
Dromerick, A. W. et al. Critical Period after Stroke Study (CPASS): a phase II clinical trial testing an optimal time for motor recovery after stroke in humans. Proc. Natl Acad. Sci. USA 118, e2026676118 (2021).
Fawcett, J. W., Oohashi, T. & Pizzorusso, T. The roles of perineuronal nets and the perinodal extracellular matrix in neuronal function. Nat. Rev. Neurosci. 20, 451–465 (2019).
Venturino, A. et al. Microglia enable mature perineuronal nets disassembly upon anesthetic ketamine exposure or 60-Hz light entrainment in the healthy brain. Cell Rep. 36, 109313 (2021).
Grieco, S. F. et al. Subanesthetic ketamine reactivates adult cortical plasticity to restore vision from amblyopia. Curr. Biol. 30, 3591–3603.e8 (2020).
Berry, M. & Linder, C. in The Mouse in Biomedical Research 2nd edn (eds Fox, J. G. et al.) 53–78 (Elsevier, 2007).
Bohn, L. M. et al. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286, 2495–2498 (1999).
Frankish, A. et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766–D773 (2019).
More News
Author Correction: Bitter taste receptor activation by cholesterol and an intracellular tastant – Nature
Audio long read: How does ChatGPT ‘think’? Psychology and neuroscience crack open AI large language models
Ozempic keeps wowing: trial data show benefits for kidney disease